tislelizumab + docetaxel + oxaliplatin + capecitabine

This neoadjuvant combination therapy regimen, evaluated in the Phase 2 TRACE study, consists of the anti-PD-1 monoclonal antibody tislelizumab in combination with a chemotherapy backbone of docetaxel, oxaliplatin, and capecitabine. Developed for the treatment of locally advanced resectable adenocarcinoma of the esophagogastric junction (AEG), the regimen utilizes a unique induction phase of tislelizumab monotherapy followed by combination cycles. Tislelizumab, developed by BeiGene, functions as a checkpoint inhibitor by targeting the PD-1 receptor to restore anti-tumor T-cell activity. The chemotherapy components provide cytotoxic effects through microtubule stabilization (docetaxel), DNA cross-linking (oxaliplatin), and inhibition of thymidylate synthase (capecitabine). This perioperative approach is designed to improve pathological complete response rates and overall surgical outcomes in AEG patients.

Other names

neoadjuvant anti-PD-1 with DOC chemotherapytislelizumab plus docetaxel, oxaliplatin, and capecitabineTRACE regimen